Intertumoral Heterogeneity within Medulloblastoma SubgroupsFlorence M.G. Cavalli, Jaroslav Štěrba, Bolesław Lach et al.|Cancer Cell|2017Cited by 1.3k
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysisEric M. Thompson, Tibor Hortobágyi, Thomas Hielscher et al.|The Lancet Oncology|2016Cited by 369
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade GliomasÁlvaro Lassaletta, Bev Wilson, Michal Zápotocký et al.|Journal of Clinical Oncology|2017Cited by 345
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177Paul D. Brown, Jan C. Buckner, Sunil Krishnan et al.|Journal of Clinical Oncology|2008Cited by 275
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort AnalysisVijay Ramaswamy, Ralph P. Ermoian, Thomas Hielscher et al.|Journal of Clinical Oncology|2016Cited by 206